These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 18622026)

  • 1. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.
    Shan W; Palkar PS; Murray IA; McDevitt EI; Kennett MJ; Kang BH; Isom HC; Perdew GH; Gonzalez FJ; Peters JM
    Toxicol Sci; 2008 Oct; 105(2):418-28. PubMed ID: 18622026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.
    Bility MT; Zhu B; Kang BH; Gonzalez FJ; Peters JM
    Toxicol Sci; 2010 Jan; 113(1):27-36. PubMed ID: 19748995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice.
    Shan W; Nicol CJ; Ito S; Bility MT; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
    Hepatology; 2008 Jan; 47(1):225-35. PubMed ID: 18038451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice.
    Balandaram G; Kramer LR; Kang BH; Murray IA; Perdew GH; Gonzalez FJ; Peters JM
    Toxicology; 2016 Jul; 363-364():1-9. PubMed ID: 27427494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy.
    Koga T; Yao PL; Goudarzi M; Murray IA; Balandaram G; Gonzalez FJ; Perdew GH; Fornace AJ; Peters JM
    J Biol Chem; 2016 Nov; 291(48):25255-25263. PubMed ID: 27765815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.
    Borland MG; Foreman JE; Girroir EE; Zolfaghari R; Sharma AK; Amin S; Gonzalez FJ; Ross AC; Peters JM
    Mol Pharmacol; 2008 Nov; 74(5):1429-42. PubMed ID: 18687807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
    Hollingshead HE; Borland MG; Billin AN; Willson TM; Gonzalez FJ; Peters JM
    Carcinogenesis; 2008 Jan; 29(1):169-76. PubMed ID: 17893232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.
    Zhu B; Bai R; Kennett MJ; Kang BH; Gonzalez FJ; Peters JM
    Mol Cancer Ther; 2010 Dec; 9(12):3267-77. PubMed ID: 21159610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
    Hollingshead HE; Killins RL; Borland MG; Girroir EE; Billin AN; Willson TM; Sharma AK; Amin S; Gonzalez FJ; Peters JM
    Carcinogenesis; 2007 Dec; 28(12):2641-9. PubMed ID: 17693664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
    Hollingshead HE; Morimura K; Adachi M; Kennett MJ; Billin AN; Willson TM; Gonzalez FJ; Peters JM
    Dig Dis Sci; 2007 Nov; 52(11):2912-9. PubMed ID: 17404849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
    Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M
    Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro.
    Sheng L; Ye P; Liu YX; Han CG; Zhang ZY
    Clin Exp Hypertens; 2008 Feb; 30(2):109-19. PubMed ID: 18293166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of PPAR-β/δ agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury.
    Chehaibi K; le Maire L; Bradoni S; Escola JC; Blanco-Vaca F; Slimane MN
    Transl Res; 2017 Apr; 182():27-48. PubMed ID: 27818230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells.
    Zhang M; Barroso E; Peña L; Rada P; Valverde ÁM; Wahli W; Palomer X; Vázquez-Carrera M
    Biomed Pharmacother; 2024 Oct; 179():117303. PubMed ID: 39153437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.
    Foreman JE; Sharma AK; Amin S; Gonzalez FJ; Peters JM
    Cancer Lett; 2010 Feb; 288(2):219-25. PubMed ID: 19660859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.
    Zarei M; Barroso E; Palomer X; Escolà-Gil JC; Cedó L; Wahli W; Vázquez-Carrera M
    Clin Investig Arterioscler; 2019; 31(3):111-118. PubMed ID: 30987865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARβ/δ activation protects against hepatic ischaemia-reperfusion injury.
    Qian B; Wang C; Li X; Ma P; Dong L; Shen B; Wu H; Li N; Kang K; Ma Y
    Liver Int; 2023 Dec; 43(12):2808-2823. PubMed ID: 37833850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.
    Bility MT; Devlin-Durante MK; Blazanin N; Glick AB; Ward JM; Kang BH; Kennett MJ; Gonzalez FJ; Peters JM
    Carcinogenesis; 2008 Dec; 29(12):2406-14. PubMed ID: 18799709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.
    Girroir EE; Hollingshead HE; Billin AN; Willson TM; Robertson GP; Sharma AK; Amin S; Gonzalez FJ; Peters JM
    Toxicology; 2008 Jan; 243(1-2):236-43. PubMed ID: 18054822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
    Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
    Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.